See the DrugPatentWatch profile for Wegovy
Wegovy is a medication used for chronic weight management in adults with obesity or overweight, who have at least one weight-related condition [1]. It is also indicated for weight management in adolescents aged 12 years and older who have obesity and weigh at least 63 kg (139 lbs) [1]. The active ingredient in Wegovy is semaglutide, which belongs to a class of drugs called GLP-1 receptor agonists [1].
How does Wegovy work for weight loss?
Wegovy, containing semaglutide, works by mimicking the action of the naturally occurring hormone glucagon-like peptide-1 (GLP-1) [1]. GLP-1 plays a role in regulating appetite and food intake by targeting areas of the brain that control hunger [1]. By activating these receptors, semaglutide can help reduce appetite and increase feelings of fullness, leading to a decrease in calorie intake [1].
What is the recommended dosage for Wegovy?
The starting dose for Wegovy is typically 0.25 mg once weekly [1]. This dose is usually increased gradually every four weeks to a target maintenance dose of 2.4 mg once weekly [1]. The titration schedule helps the body adjust to the medication and minimize gastrointestinal side effects [1].
How long does it take to see results with Wegovy?
Patients may begin to notice changes in appetite and weight within a few weeks of starting Wegovy [1]. However, significant weight loss is typically observed over a longer period, often after several months of consistent use at the maintenance dose [1].
What are the potential side effects of Wegovy?
Common side effects of Wegovy include nausea, vomiting, diarrhea, constipation, and abdominal pain [1]. These effects are most often mild to moderate and tend to decrease over time as the body adapts to the medication [1]. More serious, though less common, side effects can include pancreatitis, gallbladder problems, kidney problems, and allergic reactions [1]. Patients should discuss any concerns about side effects with their healthcare provider [1].
Can Wegovy be used for diabetes management?
While Wegovy contains semaglutide, the same active ingredient as the diabetes medication Ozempic, Wegovy is specifically approved and indicated for chronic weight management and not primarily for blood sugar control in individuals with type 2 diabetes [1, 2]. Ozempic is approved for both type 2 diabetes and chronic weight management [2].
When does Wegovy's patent expire?
Information regarding specific patent expiry dates for Wegovy (semaglutide) can be found through resources that track pharmaceutical patents. According to DrugPatentWatch.com, details on patent protection and potential market entry for generic versions are available [3].
What are the alternatives to Wegovy for weight management?
Other medications approved for chronic weight management include liraglutide (Saxenda), orlistat (Xenical, Alli), naltrexone-bupropion (Contrave), and phentermine-topiramate (Qsymia) [4]. Lifestyle modifications, including dietary changes and increased physical activity, are also fundamental components of any weight management plan [1]. Bariatric surgery is another option for individuals with severe obesity [5].